These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34792893)

  • 1. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19].
    Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
    Mroz M; Mućka S; Miodońska M; Ziolkowska D; Hadas E; Bożek A
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577804
    [No Abstract]   [Full Text] [Related]  

  • 3. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
    Gelfand JM; Armstrong AW; Bell S; Anesi GL; Blauvelt A; Calabrese C; Dommasch ED; Feldman SR; Gladman D; Kircik L; Lebwohl M; Lo Re V; Martin G; Merola JF; Scher JU; Schwartzman S; Treat JR; Van Voorhees AS; Ellebrecht CT; Fenner J; Ocon A; Syed MN; Weinstein EJ; Gondo G; Heydon S; Koons S; Ritchlin CT
    J Am Acad Dermatol; 2021 May; 84(5):1254-1268. PubMed ID: 33422626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
    Gisondi P; Geat D; Bellinato F; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).
    Parthasaradhi A; Ganguly S; Kar BR; Thomas J; Neema S; Tahiliani S; Sathishkumar D; Parasramani SG; Chalam KV; Komeravalli H
    Indian J Dermatol Venereol Leprol; 2022; 88(3):286-290. PubMed ID: 35434988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
    Sadeghinia A; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14498. PubMed ID: 33141519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.
    Ciechanowicz P; Dopytalska K; Mikucka-Wituszyńska A; Dźwigała M; Wiszniewski K; Herniczek W; Szymańska E; Walecka I
    J Dermatolog Treat; 2022 May; 33(3):1581-1584. PubMed ID: 33317364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.
    Aryanian Z; Balighi K; Hatami P; Goodarzi A; Mohandesi NA; Afshar ZM
    Dermatol Ther; 2022 May; 35(5):e15430. PubMed ID: 35261123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and psoriasis: biologic treatment and challenges.
    Ebrahimi A; Sayad B; Rahimi Z
    J Dermatolog Treat; 2022 Mar; 33(2):699-703. PubMed ID: 32598204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents.
    Talamonti M; Galluzzo M
    Expert Opin Biol Ther; 2021 Nov; 21(11):1535-1537. PubMed ID: 34357839
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.
    Zou Y; Xu J; Chen AJ; Huang K; Zhu SM; Li JJ; He J; Li JZ; Xiong JX; Fan YK; Liu C; Pan Y; Wang P
    Sci Rep; 2024 Mar; 14(1):6331. PubMed ID: 38491005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.
    Musumeci ML; Caruso G; Trecarichi AC; Micali G
    Dermatol Ther; 2022 Jan; 35(1):e15177. PubMed ID: 34699117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.
    Lodde GC; Krefting F; Placke JM; Schneider L; Fiedler M; Dittmer U; Becker JC; Hölsken S; Schadendorf D; Ugurel S; Sondermann W
    Front Immunol; 2023; 14():1107438. PubMed ID: 37006279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting.
    Mease PJ; Calabrese LH; Duffin KC; Haberman RH; Firmino R; Scher JU; Schick L; Winthrop K; Merola JF
    J Rheumatol Suppl; 2021 Jun; 97():24-29. PubMed ID: 34074662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.